SCHEMBL17540948

SCHEMBL17540948

CCOC(=O)c1cc(Cl)c2cc(C)ncc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 4/20 0.44
MAPT P10636 4/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 1/20 0.44
XBP1 P17861 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TLR9 Q9NR96 1/20 0.44
CYP1A2 P05177 1/20 0.42
NOTUM Q6P988 1/20 0.41
GLP1R P43220 1/20 0.40
GABRA2 P47869 7/20 0.40
GABRB2 P47870 6/20 0.40
GABRA1 P14867 6/20 0.40
GABRG2 P18507 6/20 0.40
GABRB3 P28472 6/20 0.40
GABRA5 P31644 6/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23198681 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2NPC1MAPTHTT
SCHEMBL23198684 0.86 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1MAPTHTT
SCHEMBL30474276 0.80 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1MAPTHTT
SCHEMBL23202573 0.80 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1MAPTHTT
SCHEMBL9729781 0.80 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2MAPTMAPK1CYP1A2
SCHEMBL9319008 0.78 TNF (0.50) ALDH1A1SMN1; SMN2MAPTHTTTP53
SCHEMBL163381 0.78 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2MAPTNPSR1CYP1A2
SCHEMBL23198535 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1MAPTCYP1A2
SCHEMBL31254231 0.77 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPC1MAPTCYP1A2
SCHEMBL25893827 0.77 CYP1A2 (0.43) ALDH1A1SMN1; SMN2NPC1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3185865-B1 TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. MERCK SHARP & DOHME (US) 2020-07-15 EP disclosed
US-10072003-B2 Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use MERCK SHARP & DOHME CORP. 2018-09-11 US disclosed
US-20170305902-A1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-10-26 US disclosed
EP-3185865-A1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE Merck Sharp & Dohme Corp. (US) 2017-07-05 EP disclosed
WO-2016029454-A1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-03-03 WO disclosed
WO-2016032921-A1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072003-B2 Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use GRIN2A, GRIN2C, GRIN2B ALDH1A1 4527/4885SMN1; SMN2 548/4885NPC1 959/4885
US-20170305902-A1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRIN2A, GRIN2C, GRIN2B ALDH1A1 4527/4885SMN1; SMN2 548/4885NPC1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.